top of page

PCOS Research Study
 

Dr. Anuja Dokras and the PCOS Center at the University of Pennsylvania is running a research study for individuals with polycystic ovarian syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD).

Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease which is characterized by liver injury and inflammation. PCOS is a common endocrine abnormality in women of reproductive age and is characterized by affecting ovulation and excessive hair growth in women.

 

The study will involve approximately 24-weeks of treatment using an investigational drug, Saroglitazar Magnesium. Saroglitazar Magnesium is investigational and has not been approved by the U.S. Food and Drug Administration. The purpose of this study is to evaluate the efficacy and safety of Saroglitazar Magnesium 4 mg tablet once daily in women with well characterized PCOS diagnosed with NAFLD.

 

If you are eligible to participate you have a 50% chance of receiving the study drug or a placebo (sugar pill).

 

Study participants must:

  • Be between 18-45 years of age

  • Have a diagnosis of PCOS

  • Have NAFLD or Suspected NAFLD

 

Study involvement may include:

  • Frequent Clinic Visits

  • Blood Draws

  • Physical and Gynecological Exams

  • MRIs and FibroScans

  • Study Medication or Placebo

  • Compensation for time and travel

 

For more information please click HERE or call 215.662.7727.

 

Principal Investigator:  Anuja Dokras, MD, PhD

© 2017 by Penn Medicine Women's Health Clinical Research Center

University of Pennsylvania, Philadelphia PA

(215) 662-7727

bottom of page